Cargando…

Engineering Nanoplatform for Combined Cancer Therapeutics via Complementary Autophagy Inhibition

Despite advances in the development of tumor treatments, mortality from cancer continues to increase. Nanotechnology is expected to provide an innovative anti-cancer therapy, to combat challenges such as multidrug resistance and tumor recurrence. Nevertheless, tumors can greatly rely on autophagy as...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xuan, Li, Yunhao, Lu, Jianqing, Deng, Xiongwei, Wu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776236/
https://www.ncbi.nlm.nih.gov/pubmed/35054843
http://dx.doi.org/10.3390/ijms23020657
_version_ 1784636783519072256
author Wang, Xuan
Li, Yunhao
Lu, Jianqing
Deng, Xiongwei
Wu, Yan
author_facet Wang, Xuan
Li, Yunhao
Lu, Jianqing
Deng, Xiongwei
Wu, Yan
author_sort Wang, Xuan
collection PubMed
description Despite advances in the development of tumor treatments, mortality from cancer continues to increase. Nanotechnology is expected to provide an innovative anti-cancer therapy, to combat challenges such as multidrug resistance and tumor recurrence. Nevertheless, tumors can greatly rely on autophagy as an alternative source for metabolites, and which desensitizes cancer cells to therapeutic stress, hindering the success of any current treatment paradigm. Autophagy is a conserved process by which cells turn over their own constituents to maintain cellular homeostasis. The multistep autophagic pathway provides potentially druggable targets to inhibit pro-survival autophagy under various therapeutic stimuli. In this review, we focus on autophagy inhibition based on functional nanoplatforms, which may be a potential strategy to increase therapeutic sensitivity in combinational cancer therapies, including chemotherapy, radiotherapy, phototherapy, sonodynamic therapy, and immunotherapy.
format Online
Article
Text
id pubmed-8776236
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87762362022-01-21 Engineering Nanoplatform for Combined Cancer Therapeutics via Complementary Autophagy Inhibition Wang, Xuan Li, Yunhao Lu, Jianqing Deng, Xiongwei Wu, Yan Int J Mol Sci Review Despite advances in the development of tumor treatments, mortality from cancer continues to increase. Nanotechnology is expected to provide an innovative anti-cancer therapy, to combat challenges such as multidrug resistance and tumor recurrence. Nevertheless, tumors can greatly rely on autophagy as an alternative source for metabolites, and which desensitizes cancer cells to therapeutic stress, hindering the success of any current treatment paradigm. Autophagy is a conserved process by which cells turn over their own constituents to maintain cellular homeostasis. The multistep autophagic pathway provides potentially druggable targets to inhibit pro-survival autophagy under various therapeutic stimuli. In this review, we focus on autophagy inhibition based on functional nanoplatforms, which may be a potential strategy to increase therapeutic sensitivity in combinational cancer therapies, including chemotherapy, radiotherapy, phototherapy, sonodynamic therapy, and immunotherapy. MDPI 2022-01-07 /pmc/articles/PMC8776236/ /pubmed/35054843 http://dx.doi.org/10.3390/ijms23020657 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wang, Xuan
Li, Yunhao
Lu, Jianqing
Deng, Xiongwei
Wu, Yan
Engineering Nanoplatform for Combined Cancer Therapeutics via Complementary Autophagy Inhibition
title Engineering Nanoplatform for Combined Cancer Therapeutics via Complementary Autophagy Inhibition
title_full Engineering Nanoplatform for Combined Cancer Therapeutics via Complementary Autophagy Inhibition
title_fullStr Engineering Nanoplatform for Combined Cancer Therapeutics via Complementary Autophagy Inhibition
title_full_unstemmed Engineering Nanoplatform for Combined Cancer Therapeutics via Complementary Autophagy Inhibition
title_short Engineering Nanoplatform for Combined Cancer Therapeutics via Complementary Autophagy Inhibition
title_sort engineering nanoplatform for combined cancer therapeutics via complementary autophagy inhibition
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776236/
https://www.ncbi.nlm.nih.gov/pubmed/35054843
http://dx.doi.org/10.3390/ijms23020657
work_keys_str_mv AT wangxuan engineeringnanoplatformforcombinedcancertherapeuticsviacomplementaryautophagyinhibition
AT liyunhao engineeringnanoplatformforcombinedcancertherapeuticsviacomplementaryautophagyinhibition
AT lujianqing engineeringnanoplatformforcombinedcancertherapeuticsviacomplementaryautophagyinhibition
AT dengxiongwei engineeringnanoplatformforcombinedcancertherapeuticsviacomplementaryautophagyinhibition
AT wuyan engineeringnanoplatformforcombinedcancertherapeuticsviacomplementaryautophagyinhibition